IWP
MBRX icon

Icon Wealth Partners’s Moleculin Biotech MBRX Stock Holding History

Icon Wealth Partners’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1
Closed -$1K – 524
2019
Q1 		$1K Buy
+1
New +$2.98K ﹤0.01% 868

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WIC
Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Icon Wealth Partners's MBRX Position: Q2 2019 in Review

Icon Wealth Partners sold out of Moleculin Biotech (MBRX) in Q2 2019, closing a stake of 1 share — an estimated $1K sold.

Icon Wealth Partners first reported a position in MBRX in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 19 funds tracked by Wall St. Rank hold MBRX as of Q2 2019.

  • Icon Wealth Partners reported no remaining Moleculin Biotech position as of Q2 2019 after selling out during the quarter.
  • Icon Wealth Partners sold 1 Moleculin Biotech share in Q2 2019, an estimated $1K.
  • Icon Wealth Partners first reported a position in Moleculin Biotech in Q1 2019 and held it in 1 quarter.
  • Icon Wealth Partners's Moleculin Biotech position peaked at $1K in Q1 2019.
  • 19 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2019.

Based on Icon Wealth Partners's 13F filing for Q2 2019, filed 13 Aug 2019.